Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.67 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losartan SCHEMBL29383742 | 1.00 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6092394 | 1.00 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL4726128 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL7420948 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL17653801 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL17653794 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL42080 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL3216357 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL4090171 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL28370801 | 0.99 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46390 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747238-A1 | PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS | Sanofi (FR) | 2026-05-27 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260109755-A1 | SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof | CELROS BIOTECH (KR) | 2026-04-23 | — | — | US | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | claimed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | claimed |
| WO-1992010183-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | claimed |
| EP-0480659-A2 | Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| WO-1992000067-A2 | TREATMENT OF CHRONIC RENAL FAILURE WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-09 | — | — | WO | claimed |
| WO-1991015206-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-17 | — | — | WO | claimed |
| WO-1991014367-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-03 | — | — | WO | claimed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | claimed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | claimed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | claimed |